Dr Michael-Robin Witt holds a Ph.D. in Neuropharmacology from the Royal School of Pharmacy, Copenhagen, Denmark. He has published more than 50 publications in peer-reviewed scientific journals. Following 12 years in academic research, at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark. Dr Witt has held senior line and project management positions in Scandinavian Biotech companies including Neurosearch AB (1999-2000), AstraZeneca R&D (2000-2003), KaroBio AB (2003-2007). In 2007, Dr Witt co-founded Axcentua Pharmaceuticals AB, acting as CSO for 5 years before joining Lead Discovery Malaysia in 2012 where he currently holds the positions of CEO & CSO. Dr Witt joined Gabather AB in September 2014 and was appointed Principal Scientist in October 2015. He is currently CEO.
Shares: 24 900
Warrants 22/25: 50 000
Dr Christine Natasha Ryan holds a PhD in Neuroscience from the University of Cambridge, Cambridge, UK and an MBA from Stockholm School of Economics. Following a post-doc at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark, Dr Ryan remained in Scandinavia moving to Sweden to work at Astra, which then became AstraZeneca, holding line management and competitive intelligence roles. Dr Ryan has engaged in preclinical research at blue chip companies such as AstraZeneca, smaller pharmaceutical companies, CROs and biotechs, working at Karo Bio AB, and Cerca Insights among others. Dr Ryan joined Gabather AB as Principal Scientist in 2017, becoming VP Operations in 2018. She is currently COO.
Shares: 10 650
Dr. Stefan Rehnmark holds a PhD in Physiology from the Wenner-Gren Institute, Stockholm University, where he also is appointed Associate Professor. After more than 10 years of academic research he moved to the Biotech industry, where he has been working for more than 20 years, holding several positions, such as Head of Molecular Biology, Head of Pharmacology, Project Manager and Principal Scientist. In 2007, Dr Rehnmark co-founded Axcentua Pharmaceuticals AB, where he served as CSO and CEO. In 2014, Dr Rehnmark co-founded Noviga Research, a Biotech company active in the development of oncology therapeutics. Dr Rehnmark joined Gabather AB as Principal Scientist in August 2016 and became VP Scientific affairs in 2018. He is currently CSO.
Shares: 28 666
Warrants 22/25: 50 000
Kristofer Svensson has a master's degree in economics from Stockholm University. He has also studied psychology and has experience from the Swedish Armed Forces. Kristofer has several years of experience in financial management and financing as CFO in the pharmaceutical industry.
Warrants 22/25: 25 000